Bionano GenomicsBNGOW 64 Current Ratio is 1.84 as of Mar. 2026, which is 13% below its 10-year median of 2.12. GuruFocus rates BNGOW with a GF Score™ of 64/100. The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Bionano Genomics ranks worse than 65.61% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bionano Genomics's current ratio for the quarter that ended in Mar. 2026 was 1.84.
Bionano Genomics has a current ratio of 1.84. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bionano Genomics's Current Ratio or its related term are showing as below:
BNGOW'
s Current Ratio Range Over the Past 10 Years
Min: 0.43 Med: 2.12 Max: 51.65
Current: 1.84
During the past 10 years, Bionano Genomics's highest Current Ratio was 51.65. The lowest was 0.43. And the median was 2.12.
BNGOW's Current Ratio is ranked worse than 65.61% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 2.47
vs BNGOW: 1.84
Bionano Genomics (NAS:BNGOW) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Bionano Genomics Current Ratio Related Terms
Bionano Genomics Current Ratio Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNGOW vs UEEC, CUPR, FEMY: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (BNGOW) has a Current Ratio of 1.84 as of Mar. 2026. This is 13% below median its historical median of 2.12. Over the past decade, Bionano Genomics' Current Ratio has ranged from 0.43 to 51.65. According to the industry distribution chart, Bionano Genomics ranks #561 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 65.6%.
Is Bionano Genomics' Current Ratio too high?
Bionano Genomics' current Current Ratio of 1.84 is 13% below median its 10-year median of 2.12. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 51.65. The Medical Devices & Instruments industry median Current Ratio is 2.47. Bionano Genomics' value of 1.84 is 25.5% below this industry median. Based on the distribution chart, Bionano Genomics ranks #561 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Current Ratio compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #561 out of 855 companies for Current Ratio. This places Bionano Genomics in the lower half of its industry. The industry median Current Ratio is 2.47. Bionano Genomics' value of 1.84 is 25.5% below this benchmark. Historically, Bionano Genomics' own Current Ratio has ranged from 0.43 to 51.65 over the past decade. While the company's 10-year median is 2.12 vs. the industry median of 2.47, Bionano Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.47, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current Current Ratio of 1.84 is 25.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Current Ratio is 1.84, which is 13% below median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current Current Ratio of 1.84. The current Current Ratio is 1.84, which is 13% below median its 10-year median of 2.12 and 25.5% below the Medical Devices & Instruments industry median of 2.47. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current Current Ratio is 1.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score
Get the complete analysis for BNGOW
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 
